

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Rigdon Lentz

Serial No.: 09/709,045 Art Unit: 1647

Filed: November 10, 2000 Examiner: Lorraine Spector

For: *METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. § 1.97, Applicant submits a Supplemental Information Disclosure Statement, including three (3) pages of Form PTO-1449 and copies of twelve (12) documents cited therein. Pursuant to the waiver in the notice entitled "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications Filed After June 30, 2003" published on August 5, 2003 in 1273 OG 55, copies of the U.S. Patents cited below are not enclosed. However, copies will be provided upon request.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(d) after a Notice of Appeal. The Commissioner is authorized to charge \$180.00, the fee set forth under 37 CFR § 1.17(p), to Account No. 50-3129. It is believed that no additional fee is required with this submission. However, should an additional fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-3129.

U.S.S.N.: 09/709,045
Filed: November 10, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Certification Under 37 C.F.R. §1.97 (e)(2)

Each item of information listed below this certification in this Supplemental Information Disclosure Statement was not cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, each item listed below was not known to any individual designated in § 1.56(e) more than three months prior to the filing of this Supplemental Information Disclosure Statement.

U.S. Patents

| <u>Number</u> | <u>Issue Date</u> | <u>Patentee</u> | <u>Class/Subclass</u> |
|---------------|-------------------|---------------------|-----------------------|
| 5,403,917 | 04-04-1995 | Boos, et al. | 530/351 |
| 5,597,899 | 01-28-1997 | Banner, et al. | 530/351 |
| 5,736,138 | 04-07-1998 | Pfizenmaier, et al. | 424/143.1 |
| 6,262,127 | 07-17-2001 | Acemoglu, et al. | 514/772.7 |
| 6,774,102 | 08-10-2004 | Bell, et al. | 514/2 |
| 7,105,484 | 09-12-2006 | Klein, et al. | 514/12 |
| 7,368,295 | 05-06-2008 | Tovar, et al. | 436/526 |

U.S. Published Applications

| <u>Number</u> | <u>Publication Date</u> | <u>Applicant</u> | <u>Class/Subclass</u> |
|---------------|-------------------------|------------------|-----------------------|
| 2007/0065514 | 03-22-2007 | Howell, et al. | 424/489 |
| 2008/0075690 | 03-27-2008 | Howell, et al. | 424/85.1 |
| 2008/0275376 | 11-06-2008 | Howell, et al. | 604/5.04 |

Foreign Documents

| <u>Number</u> | <u>Publication Date</u> | <u>Patentee</u> | <u>Country</u> |
|---------------|-------------------------|--|----------------|
| 289896 | 07-08-1992 | Terumo Kabushiki Kaisha and Hematogenetics Corp. | EP |

U.S.S.N.: 09/709,045
Filed: November 10, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

| | | | |
|--------------|------------|--|-----|
| 334165 | 12-27-1995 | Hoffman La Roche | EP |
| 787500 | 12-01-1999 | Bellco Spa | EP |
| 589982 | 01-17-2001 | Boehringer Ingelheim International | EP |
| WO 90/009798 | 09-07-1990 | Immunotherapeutics, Inc. | PCT |
| WO 93/012142 | 06-24-1993 | Tanox Biosystems, Inc. | PCT |
| WO 94/009137 | 04-28-1994 | Genetech, Inc. | PCT |
| WO 94/026924 | 11-24-1994 | Ministero Dell'Universita E Della Ricerca Scientifica E Technologica | PCT |
| WO 05/037865 | 04-28-2005 | ZymoGenetics, Inc. | PCT |
| WO 06/002151 | 01-05-2006 | Hemo-life Medical, Inc. | PCT |
| WO 08/115597 | 09-25-2008 | Cytologic, Inc. | PCT |

Publications

RIVAS, et al., "Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer", *Blood*, 91:1037-47 (1998).

U.S.S.N.: 09/709,045
Filed: November 10, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

/ Patrea L. Pabst /

Patrea L. Pabst
Reg. No. 31,284

Dated: March 9, 2009
PABST PATENT GROUP LLP
1545 Peachtree Street NE
Suite 320
Atlanta, Georgia 30309
(404) 879-2151 (Telephone)
(404) 879-2160 (Fax)